{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000021","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.121188+00:00","generated_at":"2026-06-26T05:17:53.443878+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Amphastar subsidiary enters contract manufacturing deal with related party Hanxin for Chinese market","bullets":["ANP will manufacture APIs and finished products on cost-plus basis for Hanxin, which will file for Chinese marketing authorizations.","Hanxin, majority-owned by Drs. Zhang, Luo and family, is a related party; deal approved by independent disinterested directors.","Hanxin commits to minimum purchase quantities under the agreement dated April 19, 2022; material terms to be filed with Q2 2022 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000021","json":"https://secwatch.observer/filing/0001297184-22-000021.json","markdown":"https://secwatch.observer/filing/0001297184-22-000021.md","text":"https://secwatch.observer/filing/0001297184-22-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000021/0001297184-22-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000021/amph-20220419x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:17:53.443878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}